UBS Group
NKTR icon

UBS Group’s Nektar Therapeutics NKTR Stock Holding History

UBS Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-267
Closed -$50K – 8550
2015
Q2 		$50K Sell
267
-66
-20% -$11.4K ﹤0.01% 6008
2015
Q1 		$55K Buy
+333
New +$68.4K ﹤0.01% 5946

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

UBS Group's NKTR Position: Q3 2026 in Review

UBS Group reduced its Nektar Therapeutics (NKTR) stake by 38% in Q3 2026, selling an estimated $11.4M and leaving 265,873 shares worth $16.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2901.

UBS Group first reported a position in NKTR in Q4 2014 and has held it in 48 quarters since. The position peaked at $29.9M in Q2 2026. 168 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • UBS Group held 265,873 shares of Nektar Therapeutics worth $16.1M as of Q3 2026.
  • UBS Group sold 162,527 Nektar Therapeutics shares in Q3 2026, an estimated $11.4M.
  • Nektar Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2901 holding.
  • UBS Group first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 48 quarters since.
  • UBS Group's Nektar Therapeutics position peaked at $29.9M in Q2 2026.
  • 168 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.